Literature DB >> 27801755

The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians.

W Glenn McCluggage1, Lynn Hirschowitz, C Blake Gilks, Nafisa Wilkinson, Naveena Singh.   

Abstract

Accumulating recent evidence suggests that the majority of extrauterine high-grade serous carcinomas (HGSCs) do not arise from the ovary as historically accepted but from the distal, fimbrial end of the fallopian tube from a precursor known as serous tubal intraepithelial carcinoma. There has been variable acceptance of this evidence among pathologists and clinicians dealing with "ovarian" cancer and this has resulted in wide variation in the assignment of primary site between different institutions when HGSC involves >1 anatomic site. This has obvious implications for cancer epidemiology, registration, and entry into clinical trials. We undertook a survey of members of several national and international gynecologic pathology and clinical cancer societies with a view to ascertaining the degree of acceptance of the fallopian tube origin of extrauterine HGSC and to explore various aspects regarding site assignment, pathologic sampling, diagnosis, FIGO staging, and reporting of these neoplasms. The results indicate wide acceptance among both pathologists and clinicians of the fallopian tube theory of origin of HGSC (86% pathologists, 92% clinicians), although there is significant variation regarding the perceived importance of assigning a primary site given the limited prognostic and therapeutic significance. Interestingly, clinicians feel it is more important to assign a primary site than pathologists (71% vs. 49%). The survey also indicates widespread acceptance of recently proposed criteria for site assignment in extrauterine HGSC.

Entities:  

Mesh:

Year:  2017        PMID: 27801755     DOI: 10.1097/PGP.0000000000000336

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  7 in total

1.  Human Endometriosis Tissue Microarray Reveals Site-specific Expression of Estrogen Receptors, Progesterone Receptor, and Ki67.

Authors:  Mariano Colón-Caraballo; Miosotis García; Adalberto Mendoza; Idhaliz Flores
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-08

2.  Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.

Authors:  Naveena Singh; Asma Faruqi; Friedrich Kommoss; W Glenn McCluggage; Giorgia Trevisan; Janine Senz; Amy Lum; C Blake Gilks; Michael Anglesio
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

3.  Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries.

Authors:  Britton Trabert; Sally B Coburn; Andrea Mariani; Hannah P Yang; Philip S Rosenberg; Gretchen L Gierach; Nicolas Wentzensen; Kathy A Cronin; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

4.  Pathologic Classification of Ovarian Cancer.

Authors:  Stephanie M McGregor
Journal:  Methods Mol Biol       Date:  2022

5.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Authors:  Goli Samimi; Britton Trabert; Máire A Duggan; Jennifer L Robinson; Kisha I Coa; Elizabeth Waibel; Edna Garcia; Lori M Minasian; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2018-03       Impact factor: 5.482

Review 6.  Cell Origins of High-Grade Serous Ovarian Cancer.

Authors:  Jaeyeon Kim; Eun Young Park; Olga Kim; Jeanne M Schilder; Donna M Coffey; Chi-Heum Cho; Robert C Bast
Journal:  Cancers (Basel)       Date:  2018-11-12       Impact factor: 6.639

7.  Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study.

Authors:  Yiying Wang; Shuhui Hong; Jingyi Mu; Yue Wang; Jayanthi Lea; Beihua Kong; Wenxin Zheng
Journal:  J Oncol       Date:  2019-03-05       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.